Physician profile
Barry W Webb
NPI 1053399709
$4,439.94
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $399 · 2021: $1,077 · 2022: $989 · 2023: $730 · 2024: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $696.05 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $601.62 | 2019-2024 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $425.36 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $274.35 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.85 | 2019-2024 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $244.03 | 2019-2024 | Airsupra, Farxiga |
| Pfizer INC. | $242.96 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $193.64 | 2019-2023 | Steglatro, Belsomra, Gardasil 9 |
| Exact Sciences Corporation | $172.86 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $152.40 | 2019-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $135.53 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $134.20 | 2019-2022 | |
| Corium, LLC | $90.43 | 2022-2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $84.10 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.12 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.